Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JTO.0000268640.56073.d1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simpson-Golabi-Behmel syndrome type 1 in a neonate with central hepatoblastoma.
BMJ Case Rep
January 2025
Division of Neonatology, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
We report a neonate evaluated for hepatomegaly during hospitalisation and was diagnosed to have hepatoblastoma, an uncommon childhood malignancy. The presence of dysmorphism, macrosomia and congenital heart defect led to the suspicion of congenital overgrowth conditions. The genetic evaluation revealed a pathogenic variant, conclusive of Simpson-Golabi-Behmel syndrome type 1 (SGBS1).
View Article and Find Full Text PDFLived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualitative phenomenological study in Southwest China.
BMJ Open
January 2025
Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Objectives: To explore the lived experiences of patients with advanced pancreatic cancer enrolled in a patient-reported outcomes (PROs) management programme and to preliminarily understand how PROs management influences various aspects of patient care and overall quality of life.
Design: A qualitative phenomenological study.
Setting: A national cancer care centre in Southwest China specialised in cancer care, with a comprehensive PROs management programme.
Investigating Cardiac Amyloidosis: A Primer for Clinicians.
R I Med J (2013)
February 2025
Department of Medicine, Division of Cardiology, Alpert Medical School of Brown University, Providence RI.
Cardiac amyloidosis (CA) is an infiltrative disease that results from the deposition of amyloid fibrils in the myocardium, resulting in restrictive cardiomyopathy. The amyloid fibrils are predominantly derived from two parent proteins, immunoglobulin light chain (AL) and transthyretin (ATTR), and ATTR is further classified into hereditary (ATTRv) and wild-type (ATTRwt) based on the presence or absence, respectively, of a mutation in the transthyretin gene. Once thought to be a rare entity, CA is increasingly recognized as a significant cause of heart failure due to improved clinical awareness and better diagnostic imaging.
View Article and Find Full Text PDFAlbumin-Energized NIR-II Cyanine Dye for Fluorescence/Photoacoustic/Photothermal Multi-Modality Imaging-Guided Tumor Homologous Targeting Photothermal Therapy.
J Med Chem
January 2025
Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
Endowing cyanine dyes with hydrophilicity, long blood circulation, tumor targeting, and robust therapeutic efficacy in the second near-infrared (NIR-II) window is challenging for cancer treatment. Herein, we develop cancer cell membrane-coated albumin-NIR-II cyanine dye assemblies, denoted as LZ-1105@HAm, to optimize the photophysical properties of cyanine dyes in aqueous solution for NIR-II fluorescence (FL)/photoacoustic (PA)/photothermal (PT) multimodality imaging-guided tumor homologous targeting photothermal therapy. LZ-1105@HAm exhibits good hydrophilicity, extends the half-life of blood circulation from 0.
View Article and Find Full Text PDFFeasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease.
Int J Gynecol Cancer
January 2025
Division of Gynecologic Oncology, Obstetrics & Gynecology Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Objective: This study aimed to compare perioperative outcomes and progression-free and overall survival in patients with chronic kidney disease (CKD) versus those without after hyperthermic intra-peritoneal chemotherapy (HIPEC) for ovarian cancer.
Methods: This is a retrospective, single-institution cohort study of patients with ovarian cancer treated with HIPEC at the Cleveland Clinic from January 2009 to December 2022. All patients received HIPEC with cisplatin and renal protection with mannitol and furosemide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!